Navigation Links
MabVax Therapeutics Initiates Phase II Clinical Trial of Vaccine to Prevent Recurrent Sarcoma
Date:7/22/2010

SAN DIEGO, July 22 /PRNewswire/ -- MabVax Therapeutics Inc., a privately held clinical stage biotechnology company focused on the development of vaccine and antibody based therapies to address the unmet medical need of preventing recurrent cancer, announces that the first patients have been enrolled in a Phase II clinical trial aimed at assessing the efficacy and safety of its vaccine to prevent or delay the recurrence of sarcoma. The clinical trial will enroll 126 metastatic sarcoma patients, 16 years or older in a randomized, multicenter, double-blind Phase II study of a trivalent vaccine specifically developed to target and kill residual circulating cancer cells and micrometastases thought to cause recurrent cancer.  

In the United States (US), there are approximately 13,200 sarcoma cases diagnosed each year, representing less than 1% of all new cancers.  Prognosis remains poor, with more than 5,200 patients in the US dying of disease each year.  As in other malignancies, disease recurrence and metastasis are common in sarcoma.  Despite undergoing potentially curative surgical resection or combination therapy, the majority of these patients with recurrent sarcoma die as a result of further recurrences.  The addition of chemotherapy to surgical resection has not shown to improve outcome in adult patients with sarcoma. Thus, in the majority of cases, the current standard of care following treatment of metastatic disease and the achievement of disease-free status is expectant management.

The vaccine is a trivalent ganglioside vaccine administered with an immunological adjuvant in a series of 10 subcutaneous injections given over an 84-week period.  The vaccine is intended to instruct the patient's immune system to make antibodies against the three ganglioside antigens present on the surface of sarcoma cells.  The antibodies will then seek out and kill the residual circulating cancer cells and micrometastases with the objective of preventing disease recurrence.  The vaccine was developed at Memorial Sloan-Kettering Cancer Center (MSKCC) where preclinical and early clinical development work was completed in 2009.  MabVax exclusively licensed the sarcoma vaccine, along with additional vaccines targeting other neuroectodermal and epithelial cancers, from the Sloan-Kettering Institute for Cancer Research in 2008.  

MabVax has recruited 12 leading academic medical centers across the country as investigative sites to conduct the Phase II clinical trial.  MabVax expects enrollment to require approximately 15 months. The primary objective is to determine the 1-year Progression Free Survival Rate in patients with metastatic sarcoma who are without evidence of disease and who are treated with the vaccine plus adjuvant or with the adjuvant alone.  Secondary objectives are to determine Overall Survival, Disease Free Survival, and Disease Specific Survival, along with Progression Free Survival at the 3-year time point.  MabVax has engaged Clinsys Clinical Research, Inc. as the contract clinical research organization to help it manage the study.

Patients who would like additional information are directed to the website clinicaltrials.gov where more details can be found.

About MabVax Therapeutics, Inc.

MabVax Therapeutics, Inc. is a clinical stage biotechnology company focused on the development of vaccine and antibody based therapies to address the unmet medical need of preventing recurrent cancer. The company was formed to exploit key aspects of the work of Dr. Philip Livingston and colleagues at MSKCC who have developed cancer vaccines against gangliosides and other carbohydrate antigens that are the most extensively expressed antigenic targets on the cell surface of certain cancers. The company believes that passively administered or vaccine induced antibodies against selected tumor cell surface antigens are ideally suited for eradication of free tumor cells and micrometastases that remain after initial treatment and cause cancer recurrence.  The company plans to commercially develop distinct vaccines against several different types of cancer over the coming years.  Concurrently, MabVax is leveraging the ongoing Phase I and Phase II clinical programs utilizing the licensed vaccines to create a pipeline of monoclonal antibody products based on the protective immune responses generated from patients who have been successfully immunized against targeted cancers. The company is based in San Diego, CA. MabVax has closed two Series A rounds of venture financing in February 2008 and August of 2009.  


'/>"/>
SOURCE MabVax Therapeutics Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. MabVax Therapeutics Closes Two Licensing Agreements With Sloan-Kettering Institute for Cancer Research
2. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
3. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
4. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
5. TorreyPines Therapeutics Completes Patient Enrollment in Phase IIb Clinical Trial of Tezampanel for the Treatment of Acute Migraine Headache
6. CV Therapeutics Announces Eight Abstracts Accepted for Presentation at the European Society of Cardiology Congress 2007
7. Pharmacopeia Assists the World Health Organization in the Discovery of Novel Therapeutics for the Treatment of Malaria
8. Protalix BioTherapeutics Treats First Patient in Phase III Clinical Trial of prGCD
9. TorreyPines Therapeutics Initiates a Phase I Multiple Dose Clinical Trial of Tezampanel
10. TorreyPines Therapeutics Completes Phase I Multiple Dose Clinical Trial of NGX267, a Selective M1 Agonist for the Potential Treatment of Cognitive Impairment Associated with Schizophrenia
11. Cell Therapeutics, Inc. (CTI) Launches Phase III Study for Pixantrone in Relapsed Indolent Non-Hodgkins Lymphoma (NHL)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/4/2017)... to the Centers for Disease Control and Prevention (CDC), influenza vaccination ... is helping communities across Massachusetts , Connecticut ... flu shots through the end of the month. *Some exclusions ... ... shot is by the end of October, according to the Centers for ...
(Date:10/2/2017)... Labs announces the European launch of their new low volume, high ... in Cambridge, U.K on October 4th. The ... with unprecedented speed and sensitivity while using far less sample volume ... ... ...
(Date:9/27/2017)... and NEW YORK , Sept. 27, 2017 ... mobile health and big data solutions, today announced that its MyDario product ... check your local TV listings for when The Dr. Oz Show airs ... The ... this month. ...
Breaking Medicine Technology:
(Date:10/13/2017)... N.J. (PRWEB) , ... October 13, 2017 , ... The ... Holly Day Market. Featuring a collection of specialty vendors and unique items from across ... personalized and quality-focused health and wellness services offered by the VNA. The boutique ...
(Date:10/13/2017)... ... 2017 , ... Coveros, a leader in agile coaching services ... by the Center for Medicare and Medicaid Services (CMS). The Enterprise Agile Transformation ... Agile methodologies in a consistent and high value manner across CMS programs. Coveros ...
(Date:10/12/2017)... ... , ... Planet Fitness, one of the largest and fastest growing franchisors and ... flagship location in Covington, LA at 401 N. U.S. Highway 190, in January of ... Depot in the Holiday Square shopping center. Its location allows it to serve both ...
(Date:10/12/2017)... (PRWEB) , ... October 12, 2017 , ... ... drug delivery system that we intend to develop to enable prevention of a ... lead to severe hearing loss, especially in pediatric patients. For cisplatin, hearing loss ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... of Michigan’s 2017 Best and Brightest in Wellness® by Best and Brightest. OnSite ... program on Friday, Oct. 20 from 7:30 a.m. to 2 p.m. at the ...
Breaking Medicine News(10 mins):